EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors
EValuation of the Impact of a TOpical Lotion, CG428, on Permanent Chemotherapy Induced Hair and Scalp Disorders in Cancer SUrvivors: A randoMized, Single-center, Double-blind placEbo Controlled Trial (a Pilot Study)
In the register
The register attaches this trial to CG 428 (Legacy Healthcare), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Samsung Medical Center
- Participants (registry)
- 32
- Start
- July 2016
- Primary completion
- June 2017
- Study completion
- June 2017
- Last registry update
- September 2018
- Countries
- South Korea
Conditions studied: Alopecia
Interventions: CG428, Placebo
Other trials of CG 428
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
- NCT02986412Completed
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.